Posts in category Analyst News


Two of Wall Street’s Best Analysts Are Boosting Price Targets on Alibaba Group Holding Ltd (BABA) and Paypal Holdings Inc (PYPL)

SunTrust is captivated by BABA’s powerhouse core retail; Baird deems PYPL cream of the e-commerce crop.

Read more

Advanced Micro Devices, Inc. (AMD) Has More Attractive Risk/Reward Prospects Than Intel Corporation (INTC): Top Analyst

Canaccord’s Matt Ramsay is bullish in his 3Q preview of AMD, but continues to be apprehensive on INTC.

Read more

The Setup for Skechers USA Inc (SKX) Remains Favorable: B. Riley

Jeff Van Sinderen believes that SKX shareholders’ best days are ahead.

Read more

Ladenburg Sees 35% Upside for Transenterix Inc (TRXC), RBC Gets More Cautious on Valeant Pharmaceuticals Intl Inc (VRX)

Healthcare analysts take different approaches to valuing Transenterix and Valeant.

Read more

Uniqure NV (QURE) Is Getting the Street All Fired Up on Its Gene Therapy Candidate in Hemophilia B; Oppenheimer Spotlights Efficacy/Safety Strength

Hartaj Singh believes QURE trots out an upper hand advantage with AMT-061.

Read more

Drexel Hamilton Advises to Aggressively Buy Apple Inc. (AAPL) Stock on Any Weakness Ahead of iPhone X Cycle

Notably, AAPL has reduced projections even during some of the greatest iPhone cycles, says Brian White.

Read more

Could There Be a Saving Grace Amid Amazon.com, Inc. Studio Chief Roy Price’s Disgraced Departure? Loop Capital Says Yes

Anthony Chukumba says Price had bad history, and Amazon could use a fresh revamp in Hollywood’s eyes.

Read more

Analysts Chime in on Celgene Corporation (CELG) Crohn’s Dud and Gilead Sciences, Inc. (GILD) Winning FDA Nod for Yescarta

Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.

Read more

Cantor Sheds Light on Teva Pharmaceutical Industries Ltd (ADR) (TEVA) as Novartis (NVS) Facing the Generics Pricing Heat

Louise Chen anticipates more generic pricing pressure hit 3Q earnings for generic manufacturers.

Read more

Top Analyst Says Look for Strong Revenue Growth from Facebook Inc (FB) Come 3Q Earnings Time

Youssef Squali believes strong monetization and user growth have treated FB well during the quarter.

Read more